Clinical Trials Directory

Trials / Completed

CompletedNCT00662363

Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation

Lubiprostone (Amitiza®) Compared to Standard Care in the Treatment of Postoperative Opioid-induced Constipation in Inpatient Rehabilitation Patients Following Orthopedic Procedures

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
64 (actual)
Sponsor
Shirley Ryan AbilityLab · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Patients requiring opioids for post-operative pain control following elective orthopedic procedures which has resulted in constipation symptoms, and who are in inpatient rehabilitation will be randomized to two different treatment arms: lubiprostone or senna. Baseline scores regarding constipation and a quality of life bowel questionnaire will be compared the day following 6 days of treatment intervention.

Detailed description

The purpose of this study is to assess the efficacy of Lubiprostone (Amitiza) compared to standard care for the treatment of constipation in orthopedic patients receiving opioids for pain control during inpatient rehabilitation. Lubiprostone (Amitiza®) is a locally acting chloride channel activator that increases intestinal fluid, and thus increases intestinal motility. It has been approved for chronic constipation, but not in the setting of opioid-induced constipation. Senna is a stimulant laxative that increases propulsive peristaltic activity of the colon through local effects on the mucosa. Subjects will be compared using from the Patient Assessment of Constipation (PAC) which has previously been found to be a valid and reliable way to measure constipation symptoms and clinical course. (Frank, Kleinman et al. 1999) as well as with other measures of bowel-related symptoms and functional outcomes.

Conditions

Interventions

TypeNameDescription
DRUGLubiprostone24 µg po BID given with meals for 6 days
DRUGSenna2 tabs daily for 6 days

Timeline

Start date
2008-04-01
Primary completion
2011-10-01
Completion
2011-10-01
First posted
2008-04-21
Last updated
2013-03-06
Results posted
2013-02-21

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00662363. Inclusion in this directory is not an endorsement.